Eli Lilly’s LLY gets boost as analysts cite fresh retatrutide trial results and a wider push into next-gen obesity drugs
Eli Lilly’s shares were pulled into renewed debate about long-term growth and dividend appeal after Jefferies raised its price target for the company, pointing to full clinical data for retatrutide.